Citadel Advisors
TNGX icon

Citadel Advisors’s Tango Therapeutics TNGX Stock Holding History

Citadel Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.66M Buy
181,059
+1,636
+0.9% +$40.4K ﹤0.01% 4508
2026
Q1 		$3.75M Buy
179,423
+27,543
+18% +$383K ﹤0.01% 4835
2025
Q4 		$1.35M Buy
+151,880
New +$1.31M ﹤0.01% 6759
2025
Q3 		– Sell
-55,065
Closed -$282K – 14122
2025
Q2 		$282K Sell
55,065
-51,437
-48% -$127K ﹤0.01% 9948
2025
Q1 		$146K Sell
106,502
-1,520,257
-93% -$3.73M ﹤0.01% 10918
2024
Q4 		$5.03M Sell
1,626,759
-1,067,366
-40% -$4.96M ﹤0.01% 3959
2024
Q3 		$20.7M Buy
2,694,125
+1,462,368
+119% +$14M ﹤0.01% 2014
2024
Q2 		$10.6M Buy
1,231,757
+765,639
+164% +$5.92M ﹤0.01% 2701
2024
Q1 		$3.7M Buy
466,118
+264,303
+131% +$2.83M ﹤0.01% 4441
2023
Q4 		$2M Buy
+201,815
New +$1.75M ﹤0.01% 5349
2023
Q3 		– Sell
-164,986
Closed -$548K – 15111
2023
Q2 		$548K Sell
164,986
-8,076
-5% -$29.1K ﹤0.01% 7748
2023
Q1 		$684K Sell
173,062
-192,323
-53% -$1.12M ﹤0.01% 7634
2022
Q4 		$2.65M Sell
365,385
-112,879
-24% -$794K ﹤0.01% 4961
2022
Q3 		$1.73M Buy
478,264
+64,069
+15% +$274K ﹤0.01% 5860
2022
Q2 		$1.88M Buy
414,195
+16,010
+4% +$96.9K ﹤0.01% 5660
2022
Q1 		$3.02M Sell
398,185
-63,049
-14% -$546K ﹤0.01% 5163
2021
Q4 		$5.05M Buy
461,234
+52,709
+13% +$634K ﹤0.01% 4272
2021
Q3 		$5.28M Buy
408,525
+83,137
+26% +$997K ﹤0.01% 4198
2021
Q2 		$3.69M Buy
325,388
+2,967
+0.9% +$33.3K ﹤0.01% 5113
2021
Q1 		$3.58M Sell
322,421
-36
-0% -$414 ﹤0.01% 5024
2020
Q4 		$3.69M Sell
322,457
-17,861
-5% -$188K ﹤0.01% 4219
2020
Q3 		$3.69M Buy
+340,318
New +$3.48M ﹤0.01% 3622

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Citadel Advisors's TNGX Position: Q2 2026 in Review

Citadel Advisors increased its Tango Therapeutics (TNGX) stake by 0.91% in Q2 2026, buying an estimated $40.4K and bringing the position to 181,059 shares worth $5.66M. The position accounts for ﹤0.01% of the portfolio, ranked #4508.

Citadel Advisors first reported a position in TNGX in Q3 2020 and has held it in 22 quarters since. The position peaked at $20.7M in Q3 2024. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Citadel Advisors held 181,059 shares of Tango Therapeutics worth $5.66M as of Q2 2026.
  • Citadel Advisors bought 1,636 Tango Therapeutics shares in Q2 2026, an estimated $40.4K.
  • Tango Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4508 holding.
  • Citadel Advisors first reported a position in Tango Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Citadel Advisors's Tango Therapeutics position peaked at $20.7M in Q3 2024.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.